source
- Boston Scientific unveils major restructuring, plots job cuts amid savings driveMedical device maker Boston Scientific has been a prolific dealmaker this year but is now taking a step back as it looks to make changes internally.
- Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen optionsIncyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.